Abstract
Excess weight gain is a major cause of essential hypertension, and abnormal kidney function appears to be a cause as well as a consequence of obesity hypertension. Excess renal sodium reabsorption and a hypertensive shift of pressure natriuresis play a major role in mediating increased blood pressure associated with weight gain. Activation of the renin-angiotensin and sympathetic nervous systems and physical compression of the kidneys appear to contribute to obesity-induced increases in sodium reabsorption and hypertension.
Similar content being viewed by others
References and Recommended Reading
Flegal KM, Carroll MD, Kuczmarski RJ, et al.: Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998, 22:39–47. This paper summarizes data from the National Health and Nutrition Examination Survey on obesity in the United States for the past 30 years.
Kumanyika S: Obesity in black women. Epidemiol Rev 1987, 9:31–50.
Cooper RS, Rotimi CN, Ward R: The puzzle of hypertension in African-Americans. Sci Am 1999, 280:56–63.
Jones DW, Kim JS, Andrew ME, et al.: Body mass index and blood pressures in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994, 12:1433–1437.
Garrison RJ, Kannel WB, Stokes J III, et al.: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:234–251.
Van Vliet BN, Hall JE, Mizelle HL, et al.: Reduced parasympathetic control of heart rate in obese dogs. Am J Physiol 1995, 269:H629-H637.
Verwaerde P, Senard JM, Galinier M, et al.: Changes in shortterm variability of blood pressure and heart rate during the development of obesity-associated hypertension in high-fat fed dogs. J Hypertens 1999, 17:1135–1143.
Hall JE, Brands MW, Henegar JR, et al.: Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998, 25:58–64.
Carrol JF, Huang M, Hester RL, et al.: Hemodynamic alterations in hypertensive obese rabbits. Hypertension 1995, 26:465470.
Carroll JF, Summers RL, Dzielak DJ, et al.: Diastolic compliance is reduced in obese rabbits. Hypertension 1999, 33:811–815.
Gottdiener JS, Reda DJ, Materson BJ, et al.: Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994, 24:1492–1498.
Carroll JF, Braden DS, Henegar JR, et al.: Dietary sodium chloride (NaCl) worsens obesity-related cardiac hypertrophy. Fed Proc 1998, 12:A708.
Hall JE, Brands MW, Henegar JR: Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999, 892:91–107. This paper reviews the mechanisms by which obesity causes hypertension and abnormal kidney function.
Rumantir MS, Vaz M, Jennings GL, et al.: Neural mechanisms in human obesity-related hypertension. J Hypertens 1999, 17:1125–1133.
Grassi G, Servalle G, Cattaneo BM, et al.: Sympathetic activity in obese normotensive subjects. Hypertension 1995, 25:560–563.
Zappe DH, Kassab SE, Brands MW, et al.: Chronic adrenergic blockade attenuates the development of hypertension due to weight gain in dogs. FASEB J 1995, 9:A296.
Wofford MR, Adair C, Anderson DC, et al.: Alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Hypertension 1998, 32:595.
Rocchini AP, Mao HZ, Babu K, et al.: Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999, 33:548–553.
Kassab S, Kato T, Wilkins C, et al.: Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25:893–897.
Zappe DH, Capel WT, Keen HL, et al.: Role of renal afferent nerves in obesity-induced hypertension. Am J Hypertens 1996, 9:20A.
Hall JE: Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 1993, 43:1402–1417.
Hall JE, Brands MW, Zappe DH, et al.: Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin resistant dogs. Hypertension 1995, 25:994–1002.
Hildebrandt DA, Smith MJ Jr, Hall JE: Cardiovascular regulation during acute and chronic vertebral artery insulin infusion in conscious dogs. J Hypertension 1999, 17:252–260. This study shows that chronic central nervous system hyperinsulinemia does not cause hypertension in dogs.
Stepniakowski KT, Goodfriend, Egan BM: Fatty acids enhance vascular a-adrenergic sensitivity. Hypertension 1995, 25:774–778.
Grekin RJ, Dumont CJ, Vollmer AP, et al.: Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol 1997, 273:R324-R330.
Hildebrandt DA, Kirk D, Hall JE: Renal and cardiovascular responses to chronic increases in cerebrovascular free fatty acids. Fed Proc. 1999, 13:A780.
Hall JE, Shek EW, Brands MW: Is leptin a link between obesity and hypertension? Curr Opin Endocrinok Diabetes 1999, 6:225–229. This paper reviews the recent literature relevant to the hypothesis that leptin mediates increased sympathetic activity and hypertension in obesity.
Haynes WG, Morgan DA, Walsh SA, et al.: Cardiovascular consequences of obesity: role of leptin. Clin Exp Pharmacol Physiol 1998, 25:65–69. This paper reviews evidence linking leptin to increased sympathetic activity in obesity hypertension.
Mark AL, Correia M, Morgan DA, et al.: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999, 33:537–541. This review focuses on the neurobiology of obesity and suggests that the effect of weight gain to raise blood pressure is critically dependent on genetic background and leptin-mediated sympathetic activation.
Flier JS, Maratos-Flier E: Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998, 92:437–440. Leptin’s action in the hypothalamus and interactions with newly discovered neuropeptides are reviewed.
Fan W, Boston BA, Kesterson RA, et al.: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385:165–168.
Haynes WG, Morgan DA, Djalali A, et al.: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 33(Pt II):542–547. Short-term intracerebroventricular administration of leptin increased renal sympathetic nerve activity, but not brown adipose tissue sympathetic activity, through activation of hypothalamic melanocortin receptors.
Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31(Pt II):409–414. This study shows that long-term carotid artery or intravenous infusion of leptin raises blood pressure in rats.
Ogawa Y, Masuzaki H, Aizawa M, et al.: Blood pressure elevation in transgenic mice over-expressing leptin, the obese gene product (abstract). J Hypertens 1998, 16:S7.
Shek EW, Kim PK, Hall JE: Adrenergic blockade prevents leptin-induced hypertension (abstract). Fed Proc 1999, 13:A456.
Lu H, Duanmu Z, Houck C, et al.: Obesity due to high fat diet decreases the sympathetic nervous and cardiovascular responses to intracerebroventricular leptin in rats. Brain Res Bull 1998, 47:331–335.
Fruhbeck G: Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999, 48:903–908.
Hirose H, Saito I, Tsujioka M, et al.: The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. J Hypertens 1998, 16:2007–2012.
Suter PM, Locher R, Häsler E, et al.: Is there a role for the ob gene product leptin in essential hypertension? Am J Hypertens 1998, 11:1305–1311.
Hall JE, Henegar JR, Shek EW, et al.: Role of renin-angiotensin system in obesity hypertension (abstract). Circulation 1997, 96:I-33.
Robles RG, Villa E, Santirso R, et al.: Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens 1993, 6:1009–1019.
Reisen E, Weir M, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients. Hypertension 1997, 30:140–145.
Alonso-Galicia M, Dwyer TM, Herrera GA, et al.: Increased hyaluronic acid in the inner renal medulla of obese dogs. Hypertension 1995, 25:888–892.
Wesson DE, Kurtzman NA, Prommer JP: Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985, 40:235–237.
Henegar JR, Shek EW, Henegar L, et al.: Renal functional and structural changes in the early stages of obesity (abstract). Hypertension 1997, 30:474.
The National Institutes of Health. United States Renal Data System: 1994 Annual Report. Ann Arbor, MI: University of Michigan; 1994.
Pugh JA, Medina RA, Cornell JC, et al.: NIDDM is the major cause of end-stage renal disease. More evidence from a tri-ethnic population. Diabetes 1995, 44:1375–1380.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hall, J.E. Pathophysiology of obesity hypertension. Current Science Inc 2, 139–147 (2000). https://doi.org/10.1007/s11906-000-0073-4
Issue Date:
DOI: https://doi.org/10.1007/s11906-000-0073-4